Cathie Wood stocks make headlines for their potential to be at the leading edge of disruptive technologies and generate high returns. Yet, Wood’s flagship ARK Innovation ETF (NYSEARCA:ARKK) has declined 8% year-to-date (YTD). On the other hand, the S&P 500 and Nasdaq 100 have gained 3.9% and 4.6%, respectively. Now, several of her portfolio companies present potentially appealing entry points for buy-and-hold investors, given their more attractive valuations.In her search for bargains, Wood recently added t ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.9% in the last trading session to close at $84.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.9% gain over the past four weeks.Earlier this week, the company announced that the European Commission has granted conditional marketing authorization to Casgevy for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in pa ...

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's w ...

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they m ...

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - - Further strengthens balance sheet with pro forma cash position >$2.1 billion - ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transfo ...

 —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $70.01, marking a +1.71% move from the previous day. This change outpaced the S&P 500's 0.57% gain on the day. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, added 1.25%.Prior to today's trading, shares of the company had gained 6.15% over the past month. This has outpaced the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time.Analysts and investors alike will be keeping a close eye on the per ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $64.75, moving +0.12% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.07%. Elsewhere, the Dow saw an upswing of 0.35%, while the tech-heavy Nasdaq appreciated by 1.74%.The company's shares have seen an increase of 4.41% over the last month, surpassing the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93%.The investment community will be paying close attention to the earnings p ...

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world. This gives buyers a number of choices for adding investments that will make them money to their accounts.With only a few weeks left in the year, it’s clear that healthcare stocks are more than just a trend. Because they are strong and last a long time, they are a good purchase. In 2024, healthcare stocks will ...

CRISPR Therapeutics (CRSP 7.82%) soared 54% last year as growth stocks rallied and the company itself moved toward an important milestone: the approval of its very first product. The gene editing specialist won the world's first nod for a CRISPR-based gene editing therapy back in November when the U.K. authorized Casgevy for sickle cell disease and beta thalassemia. Then the U.S. went on to approve the product for both blood disorders too.What this means is CRISPR Therapeutics this year should start reporti ...